放射性药物能激活抗肿瘤免疫。
Radiopharmaceuticals heat anti-tumor immunity.
机构信息
Peking University-Tsinghua University Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
出版信息
Theranostics. 2023 Jan 1;13(2):767-786. doi: 10.7150/thno.79806. eCollection 2023.
Radiopharmaceutical therapy (RPT) has proven to be an effective cancer treatment with minimal toxicity. With several RPT agents approved by FDA, the remarkable potential of this therapy is now being recognized, and the anti-tumor immunity induced by RPT is beginning to be noticed. This review evaluates the potential of RPT for immune activation, including promoting the release of danger associated-molecular pattern molecules that recruit inflammatory cells into the tumor microenvironment, and activating antigen-presenting cells and cytotoxic T cells. We also discuss the progress of combining RPT with immunotherapy to increase efficacy.
放射性药物治疗（RPT）已被证明是一种具有最小毒性的有效癌症治疗方法。随着 FDA 批准了几种 RPT 制剂，这种治疗方法的巨大潜力正在被认识到，RPT 诱导的抗肿瘤免疫也开始受到关注。本文综述了 RPT 激活免疫的潜力，包括促进释放募集炎症细胞进入肿瘤微环境的危险相关分子模式分子，以及激活抗原提呈细胞和细胞毒性 T 细胞。我们还讨论了将 RPT 与免疫疗法相结合以提高疗效的进展。
Zotero 插件